CollPlant Biotechnologies
CLGN
15 hedge funds and large institutions have $33.1M invested in CollPlant Biotechnologies in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.47% less ownership
Funds ownership: 2.39% → 1.91% (-0.47%)
6% less funds holding
Funds holding: 16 → 15 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
36% less capital invested
Capital invested by funds: $51.9M → $33.1M (-$18.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.44M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$1.1M |
| 3 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
+$733K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$335K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
+$305K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$11.6M |
| 2 |
FA
Friess Associates
Greenville,
Delaware
|
-$4.99M |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$441K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$276K |
| 5 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$126K |
CLGN Hedge Fund Activity: Q3 2021 in Review
15 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2021, worth a combined $33.1M — down 36% from $51.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLGN and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $3.44M. The largest seller was Meitav Investment House, exiting entirely with an estimated $11.6M sold.
- 15 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2021, down from 16 in Q2 2021.
- Funds reported $33.1M of CollPlant Biotechnologies stock for Q3 2021, down 36% quarter-over-quarter.
- 4 funds opened new CollPlant Biotechnologies positions in Q3 2021 and 5 closed out, a net change of -1 holder.
- The largest CollPlant Biotechnologies buyer in Q3 2021 was ARK Investment Management, an estimated $3.44M added.
- The largest CollPlant Biotechnologies seller in Q3 2021 was Meitav Investment House, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2021.